Structure Therapeutics Inc GPCR:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:00 PM EDT37.50UNCH (UNCH)
Volume
53,862
Close
37.50
+0.31 (+0.83%)
+0.31 (+0.83%)Volume
410,843
52 week range
15.80 - 94.90
- Open37.40
- Day High38.04
- Day Low36.53
- Prev Close37.19
- 52 Week High94.90
- 52 Week High Date12/08/25
- 52 Week Low15.80
- 52 Week Low Date08/06/25
Latest On Structure Therapeutics Inc
Key Stats
- Market Cap2.665B
- Shares Out71.07M
- 10 Day Average Volume0.65M
- Dividend-
- Dividend Yield-
- Beta-1.40
Latest On Structure Therapeutics Inc
KEY STATS
- Open37.40
- Day High38.04
- Day Low36.53
- Prev Close37.19
- 52 Week High94.90
- 52 Week High Date12/08/25
- 52 Week Low15.80
- 52 Week Low Date08/06/25
- Market Cap2.665B
- Shares Out71.07M
- 10 Day Average Volume0.65M
- Dividend-
- Dividend Yield-
- Beta-1.40
RATIOS/PROFITABILITY
- EPS (TTM)-2.49
- P/E (TTM)-15.05
- Fwd P/E (NTM)-20.79
- EBITDA (TTM)-218.242M
- ROE (TTM)-15.00%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/04/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREStructure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target...
Daniel Welch
Independent Chairman of the Board
Raymond Stevens Ph.D.
Chief Executive Officer, Co-Founder, Director
Matthew Lang J.D.
Chief Operating Officer, General Counsel
Yingli Ma Ph.D.
Chief Technology Officer
Address
601 Gateway Blvd Suite 900
South San Francisco, CA
94080
United States